These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1013 related articles for article (PubMed ID: 27246191)

  • 1. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
    Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
    Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
    Weigel MT; Ghazoui Z; Dunbier A; Pancholi S; Dowsett M; Martin LA
    Breast Cancer Res; 2012 May; 14(3):R78. PubMed ID: 22608253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
    Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.
    Ribas R; Ghazoui Z; Gao Q; Pancholi S; Rani A; Dunbier A; Dowsett M; Martin LA
    Breast Cancer Res; 2014 Oct; 16(5):447. PubMed ID: 25358600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
    Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
    Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.
    Du T; Sikora MJ; Levine KM; Tasdemir N; Riggins RB; Wendell SG; Van Houten B; Oesterreich S
    Breast Cancer Res; 2018 Sep; 20(1):106. PubMed ID: 30180878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
    López-Knowles E; Wilkerson PM; Ribas R; Anderson H; Mackay A; Ghazoui Z; Rani A; Osin P; Nerurkar A; Renshaw L; Larionov A; Miller WR; Dixon JM; Reis-Filho JS; Dunbier AK; Martin LA; Dowsett M
    Breast Cancer Res; 2015 Mar; 17(1):35. PubMed ID: 25888249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
    Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
    Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
    Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
    Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer.
    Kimbung S; Lettiero B; Feldt M; Bosch A; Borgquist S
    Oncotarget; 2016 Sep; 7(37):59640-59651. PubMed ID: 27458152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
    Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer.
    Jia Y; Song Y; Dong G; Hao C; Zhao W; Li S; Tong Z
    Sci Rep; 2019 Sep; 9(1):12939. PubMed ID: 31506496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
    Bacci M; Giannoni E; Fearns A; Ribas R; Gao Q; Taddei ML; Pintus G; Dowsett M; Isacke CM; Martin LA; Chiarugi P; Morandi A
    Cancer Res; 2016 Mar; 76(6):1615-26. PubMed ID: 26795347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer.
    Katsyv I; Wang M; Song WM; Zhou X; Zhao Y; Park S; Zhu J; Zhang B; Irie HY
    Oncotarget; 2016 Oct; 7(43):69592-69605. PubMed ID: 27612429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
    Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
    BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.
    Liu H; Wang J; Zhang M; Xuan Q; Wang Z; Lian X; Zhang Q
    Breast Cancer Res Treat; 2017 Nov; 166(1):95-107. PubMed ID: 28730338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals.
    Huang J; Woods P; Normolle D; Goff JP; Benos PV; Stehle CJ; Steinman RA
    Breast Cancer Res Treat; 2017 Jan; 161(2):229-243. PubMed ID: 27853906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer.
    Nayak SR; Harrington E; Boone D; Hartmaier R; Chen J; Pathiraja TN; Cooper KL; Fine JL; Sanfilippo J; Davidson NE; Lee AV; Dabbs D; Oesterreich S
    Horm Cancer; 2015 Dec; 6(5-6):214-24. PubMed ID: 26113056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.